3 High Growth Stocks With Significant Insider Ownership On Euronext Paris
In This Article:
The French stock market has recently seen a boost, driven by optimism surrounding potential interest rate cuts by the European Central Bank and increased business activity due to the upcoming Paris Olympics. Against this backdrop of economic momentum, identifying growth companies with significant insider ownership can be particularly appealing for investors looking for strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In France
| Name | Insider Ownership | Earnings Growth |
| Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 24.8% | 36% |
| VusionGroup (ENXTPA:VU) | 13.4% | 25.7% |
| Adocia (ENXTPA:ADOC) | 11.9% | 63% |
| Icape Holding (ENXTPA:ALICA) | 30.2% | 35.1% |
| Arcure (ENXTPA:ALCUR) | 21.4% | 27.5% |
| La Fran?aise de l'Energie (ENXTPA:FDE) | 19.9% | 31.9% |
| S.M.A.I.O (ENXTPA:ALSMA) | 17.4% | 35.2% |
| Munic (ENXTPA:ALMUN) | 29.2% | 149.2% |
| MedinCell (ENXTPA:MEDCL) | 15.8% | 93.9% |
| OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 5.9% |
Let's explore several standout options from the results in the screener.
Lectra
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lectra SA provides industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific with a market cap of €1.04 billion.
Operations: Revenue segments for the company are: Americas (€172.65M), Asia-Pacific (€118.54M), and Segment Adjustment (€209.13M).
Insider Ownership: 19.6%
Lectra SA, a French growth company with high insider ownership, reported half-year sales of €262.29 million, up from €239.55 million last year. However, net income dropped to €12.51 million from €14.47 million. Despite this dip in earnings per share (€0.33 vs €0.38), analysts expect the stock price to rise by 25.8%. Lectra is trading at 47% below its estimated fair value and has no substantial insider trading activity over the past three months.
-
Navigate through the intricacies of Lectra with our comprehensive analyst estimates report here.
-
Our valuation report here indicates Lectra may be undervalued.
MedinCell
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a pharmaceutical company in France that develops long-acting injectables across various therapeutic areas, with a market cap of €526.49 million.
Operations: MedinCell generates revenue primarily from its pharmaceuticals segment, amounting to €11.95 million.
Insider Ownership: 15.8%
MedinCell S.A. reported a net loss of €25.04 million for the full year ended March 31, 2024, an improvement from last year's €32.01 million loss. Despite a slight decline in sales and revenue, the company is forecast to achieve profitability over the next three years with revenue expected to grow at 46.2% annually, outpacing market averages. Trading at 86.8% below its estimated fair value, analysts predict a stock price increase of 21.7%.